Black Rock Inc. Revance Therapeutics, Inc. Put Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RVNC
# of Institutions
28Shares Held
10.6MCall Options Held
360KPut Options Held
0-
Nuveen Asset Management, LLC Chicago, IL423KShares$1.09 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL237KShares$610,1410.0% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...